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Abstract: In order to target platinum complexes to cancer cells, 
trans-Pt(II) or trans-Pt(IV) complexes were bioconjugated to the 
cyclic peptide cRGDfK (cRGD), with affinity for α vβ3 integrin 
receptors, through their 4-picolinic acid spectator ligands. To tackle 
this goal, the Pt(II) and Pt(IV) precursors were activated at their 
carboxylic acid function and futher reacted with the cRGDfK peptide, 
to afford the bioconjugates Pt(II)-cRGD and Pt(IV)-cRGD, 
respectively. Pt(II)-cRGD was studied by 195Pt-NMR that confirmed 
the presence of the Pt(II) center. In contrast, the characterization of 
Pt(IV)-cRGD was not possible due to the tendency of this complex 
to undergo reduction to Pt(II) in solution. Thus, only the Pt(II)-cRGD 
complex was used for further biological studies, and it exhibited 
some cytotoxic activity against the HUVEC cell line, with the highest 
levels of α vβ3 expression. However, no improved effects were 
observed with respect to the Pt(II)-pic precursor. Studies by ICP-MS 
showed enhanced intracellular accumulation for Pt(II)-cRGD with 
respect to Pt(II)-pic in cancer cells. Overall, these results show that 
while Pt(II) bioconjugation enhances compound’s uptake, it did not 
translate into an increase in cytotoxicity. 
 
 
Introduction 
 
Metal-based anticancer agents are major components in the 
chemotherapeutic regime of many tumoral diseases. Platinum 
complexes are among the most used metallodrugs due to the 
widespread usage of cisplatin in the clinical setting. However, 
the clinical efficiency of cisplatin is hampered due to its low 
solubility, side effects, and poor activity versus certain tumors 
(tumor resistance).[1] In view of these limitations, research has 
been extended to new platinum analogues with the aim of 
overcoming these unwanted effects.[2] Most of this research has 
been performed with cis configuration because initial research 
reported a lack of activity of transplatin. However, several 
exceptions for non-conventional trans-[PtCl2(L)(L’)] complexes 
were reported, indicating that synthetic variations in the 
coordinating ligands could lead to new active species.[3] Based 
on aliphatic amines as spectator ligands, our research was also 
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able to demonstrate that active trans Pt(II) complexes were 
achievable.[4, 5] 
 
Both for cisplatin and trans-platinum like complexes, drug 
targeting strategies are considered important tools to enhance 
their selectivity and efficacy as antitumoral agents. Receptors 
associated with cell growth and division are often overexpressed 
in tumors, being therefore relevant for drug targeting. In 
particular, peptide receptors are overexpressed in certain tumors, 
as compared to endogenous expression levels, being such 
receptors relevant targets to achieve a specific accumulation of 
metallodrugs in tumor cells.[6] The examples of Pt compounds 
carrying bioactive peptides for specific delivery of Pt remain 
scarce. Reedijk et al have proved how platinum complexes with a 
broad library of dipeptides and tripeptides showed cytotoxic 
activity against cancer cell lines. Although such activity was not 
higher than cisplatin, structural variations on this tested series 
demonstrated a clear influence in the activity of the series.[7-9] 
With the same aims, Metzler-Nolte and coworkers achieved 
different series of metal compounds’ bioconjugates using cell 
penetrating peptides and other examples in a drug targeting and 
delivery strategy.[10, 11] 
 
Other examples found in the literature have explored a 
different series of receptors: the integrin family. Integrins are 
heterodimeric receptors that play a pivotal role in many cell–cell 
and cell–extracellular matrix interactions.[12, 13] They consist on 
transmembrane glycoproteins that contain two non-covalently 
bound α and β subunits. The integrin receptor αvβ3, also known 
as the vitronectin receptor, is expressed in endothelial cells and 
modulates cell migration and survival during angiogenesis. 
Being overexpressed in a variety of tumor cell types, such as 
gliobastoma, melanoma, ovarian, breast and prostate cancer, it 
potentiates tumor invasion and metastasis.[14] The α vβ3-integrin 
recognizes selectively extracellular matrix proteins, such as 
vitronectin or fibronectin, which contain the exposed Arg-Gly-Asp 
(RGD) sequence.[15] The discovery of the canonical RGD 
sequence motivated an intense research work on small peptide-
based molecules aimed at targeted drugs for antiangiogenic 
therapy. 
 
Lippard et al used an approach exploring the targeting ability 
of peptides such as linear and cyclic RGD and Asn-Gly-Asp 
(NGR), and synthesized a Pt(IV) series comprising mono and 
bifunctionalized complexes, which positively improved the 
cisplatin activity as a consequence of the peptide release once 
the Pt(IV) compound reduces to cisplatin (Pt(II)).[16] More 
recently, other Pt(IV) complexes functionalized with cyclic and 
multimeric RGD containing-peptides have been described. 
Interestingly, conjugation of a photoactivatable Pt(IV) pro-drug to 
a cyclic RGD-containing peptide, led to increased phototoxicity 
in melanoma cancer cells overexpressing the αvβ3-integrin 
receptor.[17] Other approach explored the possibility of 
enhancing the selectivity and potency of a Pt(IV) derivative of 
 
 
 
 
picoplatin by the conjugation with monomeric and multimeric 
cRGD peptides.[18] 
Previously, we have shown that some non-classical trans-
Pt(II) complexes with isopropylamine (ipa) and pyridine 
derivatives are active in cisplatin-resistant cell lines,[4, 5] as well 
as the corresponding Pt (IV) counterparts. Herein, we describe 
our attempts to functionalize these Pt(II)/Pt(IV) complexes with 
the cyclic RGD peptide cRGDfK, aiming to obtain compounds 
with enhanced selectivity towards their cytotoxic action (Figure 
1). 
 
 
 
The same strategy was used to functionalize the Pt(II) and 
Pt(IV) precursors with the RGD derivative, which comprised the 
prior activation of the carboxylic function of the 4-picolinic acid 
coordinated to Pt(II) or Pt(IV), followed by the subsequent 
coupling of the peptide. Hence, the synthesis of the metallated 
bioconjugates started with the peptide synthesis by a two-step 
method. First, the automated synthesis of the linear RGD 
peptide was achieved in solid-phase, followed by the cyclization 
in solution using strategies reported before.[21] The final cyclic 
peptide was characterized by mass spectrometry. 
 
The coupling of the Pt(II) and Pt(IV) precursors, herein 
designated as Pt(II)-pic and Pt(IV)-pic, respectively, to the 
cRGD peptide comprised the formation in situ of an NHS-
activated ester of the coordinated 4-picolinic acid, as depicted in 
Scheme 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Pt(II)-cRGD and Pt(IV)-cRGD proposed complexes. 
 
We have taken into consideration that cyclic RGD peptides 
are more efficient in targeting endothelial cells and have been 
extensively used for research, therapy, and diagnosis of 
neoangiogenesis.[19] Additionally, cRGDfK in particular, can be 
easily attached to the metal moieties via the lysine side chain, 
while preserving its biological activity. [19, 20]. 
To achieve our goal, we hypothesized that the conjugation of 
cRGDfK to the trans-Pt(II) or trans-Pt(IV) complexes, through a 
4-picolinic acid spectator ligand, would lead to Pt bioconjugates 
with the ability of specifically recognizing cells overexpressing 
αvβ3 receptors, with a consequent enhancement of the cytotoxic 
activity against the same cell lines. 
 
 
Results and Discussion 
 
Synthesis and Characterization 
 
By studying the functionalization of related Pt(II) and Pt(IV) 
complexes with the same cRGDfK derivative, we have 
considered that the intracellular reduction of the RGD-containing 
Pt(IV) pro-drug could contribute to further improve the selectivity 
of the cytotoxic action of the Pt(II) unit carrying the bioactive 
peptide. To clarify this issue, the comparison of the biological 
behaviour of the resulting Pt(II) and Pt(IV) bioconjugates would 
be of the greatest importance. 
 
 
 
 
Scheme 1. Synthesis pathway of the Pt(II)-cRGD complex (EDC = N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide; NHS = N-hydroxysuccinimide) 
 
 
Thereafter, the resulting Pt(II) and Pt(IV) activated esters were 
reacted with the cRGD derivative to afford the final Pt(II) and 
Pt(IV) bioconjugates. In the case of the Pt(II) bioconjugate, 
further purification (including HPLC) yielded the desired complex, 
Pt(II)-cRGD (Scheme 1), as detailed in the experimental section. 
The chemical identity of Pt(II)-cRGD was confirmed by 195Pt-
NMR and mass spectrometry (see Figure 2 and Figure S1). 
 
According to ESI-MS analysis of an aliquot of the reaction 
mixture, the anchoring of the cRGD peptide to the Pt(IV) 
complex resulted in the formation of a Pt(IV) bioconjugate, 
Pt(IV)-cRGD, with the expected molecular ion peak (ESI–MS (+) 
(m/z): 1144,28 [M+CH3CN+H]+, calc. for C36H53Cl4N11O8Pt 
1102.25 [M]+; see experimental peaks in Figure S2) 
 
Moreover, the HPLC analysis of the crude reaction mixture 
showed the presence of a major peak at tR = 25.0 min, which is 
clearly different from the retention time exhibited by Pt(II)-cRGD 
(tR = 19.8 min) under the same analytical conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Characterization of the Pt(II)-RGD complex: left: experimental and 
calculated molecular [M-H]-­­ peaks; right:195Pt-NMR spectra in MeOD. 
 
Unfortunately, all the attempts to record the 195Pt-NMR of 
Pt(IV)-cRGD were not successful (see Figure S3). Nuclear 
Magnetic Resonance (NMR) long accumulation experiments 
(overnight) finally afforded a small signal (that became stronger 
along time) in the Pt(II) area corresponding to the Pt(II)-cRGD 
complex (see Figures S4 and S5). These findings indicated that 
Pt(IV)-cRGD is not stable in solution being reduced to its Pt(II)-
pic counterpart. For this reason, no further studies were 
performed with this Pt(IV)-cRGD complex. 
 
Antitumoral activity in human cancer cell lines 
 
The antiproliferative properties of Pt(II)-cRGD and Pt(II)-pic 
were assayed by monitoring their ability to inhibit cell growth. 
Cytotoxic activity was determined on different human cancer cell 
lines: breast carcinoma cells (MDAMB231 and MCF7), ovarian 
carcinoma cells (A2780 and SKOV3) and human 
adenocarcinoma (A549). This diverse panel was chosen in order 
to perform the cytotoxicity evaluation in cell lines of different 
tumoral origins and with different levels of α vβ 3-integrin 
expression.[22] Additionally, the non-tumoral HUVEC human 
endothelial primary cell line overexpressing the α vβ3-integrin 
receptor was also tested in the same assay. A comparison 
between the activity of reference drug cisplatin (CDDP) and the 
activity of these metal compounds was performed. Using an 
appropriate range of concentrations, dose-response curves after 
long-term (72 h) exposure were obtained. From the experimental 
values, the IC50 values for the compounds were calculated 
(Table 1). 
 
In the human cell lines with no detectable expression of 
αvβ3-integrin, the new platinum(II) complex coupled to the cRGD 
peptide, Pt(II)-cRGD, did not show any measurable cytotoxic 
activity, neither an increase of such activity compared with the 
parental complex. In fact, in almost all cell lines tested, the 
conjugation of the Pt(II) complex to the carrier peptide resulted in 
a marked reduction of the cytotoxic activity. 
 
Worth of note is that in the HUVEC cell line, which has the 
highest levels of α vβ3 expression, the Pt(II)-cRGD complex 
exhibited some cytotoxic activity. Nevertheless, no marked 
increase in antiproliferative effects of Pt(II)-cRGD was detected 
in comparison with the respective parental complex in the 
HUVEC cells. In fact, the IC50 measured for Pt(II)-cRGD is only 
 
 
 
~1.4 times higher than the value obtained for Pt(II)-pic under the 
same conditions. We have reasoned that these overall results 
could possibly reflect the decreased uptake of Pt(II)-cRGD 
compared with the parental Pt(II) complex in the cell lines 
presenting a lower expression of α vβ3-integrin receptors, at 
variance with what has been observed in the case of HUVEC 
cells, where the compound could undergo an increased uptake 
due to the overexpression of the same receptors. To clarify this 
issue, we have performed cell uptake studies for the parental 
complex (Pt(II)-pic) and respective RGD derivative (Pt(II)-
cRGD) in selected cell lines, as described below. 
 
Table 1. IC50 values (expressed in M) for Pt(II)-cRGD complex, its 
precursor and CDDP, as determined by the MTT assay after 72 h of 
incubation of the compounds at 37 °C with tumoral and non-tumoral cells 
 
Cell lines 
 (αvβ3  expression) 
 
 A2780  A549  MCF7  MDA  SKOV3 HUVEC 
 (-) (-) (-)  MB231 (+) (+) (+++) 
           
Pt(II)-pic 87.67 >100 60.3 51.8 >100 60 
 ±1.2   ±1.2 ±1.3   ±11 
           
Pt(II)-cRGD >100 >100 >100 >100 >100 85 
          ±15 
           
cDDP 1.5 10.8 38.2 8.5 13.8 - 
 ±0.2 ±0.8 ±1.3 ±1.1 ±1.6  
           
 
Cellular uptake evaluation 
 
An important parameter in the cytotoxic activity of 
metallodrugs is the uptake and accumulation of the metal in cells. 
In order to rationalize the results of the cytotoxicity studies, and 
taking into consideration that the new platinum complex is a 
targeted metal-peptide conjugate, cellular uptake experiments 
were performed in the MCF7 and HUVEC cells lines. These cells 
were chosen because they present very different levels of 
expression of α vβ3 [22] and, importantly, the parental complex 
presents similar cytotoxicity values against both cell lines. 
 
After incubation of the cell lines with the complexes for 24 h, 
cells extracts were collected and the intracellular accumulation 
of Pt was measured by inductively-coupled plasma mass 
spectrometry (ICP-MS). The normalized results out of a single 
experiment are presented in Figure 3. There is a higher 
accumulation of platinum in HUVEC cells after exposure to both 
Pt(II)-pic and Pt(II)–cRGD when compared with MCF7 cells. In 
the case of the parental complex there is 100x more uptake in 
primary HUVEC cells (0.17 nmol Pt per 106cells) than in the 
breast cancer cells (0.0015 nmol Pt per 106cells), albeit 
presenting similar IC50 values in the two cell lines. Platinum 
accumulation after exposure to the peptide-metal conjugate was 
more than 36x times higher in HUVEC cells than in MCF7 cells 
(1.08 versus 0.0299 nmol Pt per 106 cells). This result is in line 
with the cytotoxicity studies and with the lower level of 
expression of α Vβ3 integrin in MCF-7 cells compared with 
HUVEC cells. 
 
 
 
 
It is important to notice that Pt(II)-cRGD showed the greatest 
increase of cell uptake relatively to the parental complex in the 
MCF7 cell line, having the lowest expression of the integrin 
receptor. However, the cell uptake values of both compounds 
are much higher in the integrin-positive HUVEC cell line, 
hampering a reliable comparison of the results obtained in the 
two different cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cell accumulation of platinum in HUVEC and MCF7 cells after 
exposure to Pt(II)-cRGD and parental Pt(II) complex (50 µM, 24 h). The 
platinum content is normalized to the cell number. The reported results are 
from one experiment. 
 
In the case of the HUVEC cell line, we believe that the enhanced 
intracellular accumulation of Pt(II)-cRGD could be due to its 
interaction with the targeted receptor at the cell surface. To 
validate this hypothesis HUVEC cells were incubated with Pt(II)-
cRGD in the presence of an excess of free cRGD to block the 
interaction with α Vβ3 integrin. We observed a decrease in 
platinum accumulation of ~40% (1.08 versus 0.61 nmol Pt per 
106 cells for Pt(II)-cRGD alone and with excess of free cRGD). 
This result points out for the possible contribution of specific 
mechanisms of uptake mediated by the αVβ3 receptor. 
 
 
Conclusions 
 
The functionalization of a Pt(II)-(ipa) core complex with the 
cyclic peptide cRGDfK has been achieved and the 
characterization completed. The resulting bioconjugate, Pt(II)-
cRGD, did not manifest a substantial increase in cytotoxic 
activity, as we originally expected, including towards the HUVEC 
cell line, overexpressing integrin receptors. However, Pt(II)-
cRGD‘s uptake was substantially increased in cancer cells, and 
in HUVEC was blocked by excess of cRGD. These results 
indicate a possible selective and specific tumor uptake for the 
biogonjugate Pt(II)-cRGD. Further studies will be required to 
elucidate the intracellular fate and stability of this new platinum 
complex. 
 
 
Experimental Section 
 
Reagents and Materials 
 
The platinum complexes trans-[PtCl2(4-picolinic acid)(isopropylamine)], Pt(II)-
(ipa) and trans-[PtCl4(4-picolinic acid)(isopropylamine)], Pt(IV)-(ipa) 
 
 
 
were prepared as described elsewhere.[4, 5] The linear peptide was 
synthesized using the Fmoc (9-fluorenylmethoxycarbonyl) strategy on a 
CEM 12-Channel Automated Peptide Synthesizer. Fmoc-amino acids 
were purchased from CEM. The acid labile 2-chlorotrityl chloride resin, 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
(PyBop) and 1-hydroxy-1H-benzotriazole (HOBt) were purchased from 
Novabiochem (Merck), whereas N,N-diisopropylethylamine (DIPEA), N-
(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC.HCl) 
and N-hydroxysuccinimide (NHS) were purchase from Sigma-Aldrich 
(Spain). 
 
Chromatographic systems 
 
HPLC analyses were performed on a Perkin Elmer LC pump 200 coupled 
to a Shimadzu SPD 10AV UV/Vis and to a Berthold-LB 509 radiometric 
detector. Analytical control and semi-preparative purifications of the linear 
and partially protected RGD and peptide conjugates was achieved on 
Supelco Discovery Bio Wide Pore C18 (250 x 4.6 mm, 5 µm) and 
Supelco Discovery Bio Wide Pore C18 (250 x 10 mm, 10 µm) ) with a 
flow rate of 1.0 mL min-1 or 2.0 mL min-1 (gradient B), respectively. 
 
Applied binary gradients 
 
Gradient A (Mobile phase: A = aqueous 0.1% CF3COOH and B = 
MeOH): 0-3 min, 0% mobile phase B; 3-3.1 min, 0 – 25 % mobile phase 
B; 3.1-9 min, 25 % mobile phase B; 9-9.1 min, 25 – 34 % mobile phase 
B; 9.1-20 min, 34 – 100 % mobile phase B; 20-25 min, 100 % mobile 
phase B; 25-25.1 min, 100 – 0 % mobile phase B; 25.1-30 min, 0 % 
mobile phase B. 
 
Gradient B (Mobile Phase A = H2O and B= ACN): 0-35 min, 55-100 % B; 
35-37 min, 100 % B; 37-38 min, 100-55% B; 38-40 min, 55 % B. 
 
Gradient C (Mobile Phase A = H2O and B= ACN): 0–3 min, 0 % B; 3 – 30 
min, 0-50 % B; 30 –33 min, 50 % B; 33–33.1 min, 100 % B; 33.1–37 min, 
100% B, 37-38 min, 100-0 % B, 38-40 min, 0% B. 
 
Peptide Synthesis 
 
The linear sequence was assembled by solid-phase peptide synthesis 
(SPPS) on 2-chlorotrityl chloride resin according to the Fmoc strategy. 
After peptide cleavage from the resin under mild acidic conditions (1% 
TFA/CH2Cl2), the solution was concentrated to 5% of the initial volume 
and a white solid was precipitated with cold water in an ice bath. The 
partially protected peptide was washed consecutively with water (three 
times), 5% aqueous NaHCO3 (twice), water (three times), 0.05 M KHSO4 
(twice), and water (six times) and lyophilized. RP-HPLC (220 nm, gradient 
B): 95% (tR = 10.4 min). ESI–MS (+) (m/z): 1031.1 [M+H])+, calc. for 
C49H 75N9O13S, 1030.24. 
 
Cyclization was performed via in situ activation with 2 equiv. of PyBop 
and with 10 equiv. of DIPEA as solid base under high-dilution conditions 
(5 mM) in CH2Cl2/DMF (11:1) for 16 h. The reaction mixture was purified 
by semipreparative RP-HPLC (220 nm, gradient A). After evaporation of 
the solvent, the compounds were deprotected with a standard cocktail 
mixture (95% TFA, 2.5% triisopropylsilane, 2.5% H2O) and precipitated 
with ice-cold diethyl ether. The compound was purified by preparative 
RP-HPLC (method B). After evaporation of the organic sovent, the 
compound was lyophilized and characterized by ESI–MS. 
 
RP-HPLC (220 nm, gradient C): 95% (tR = 14.0 min). ESI–MS (+) (m/z): 
604.6 [M+H])+, calc. for C27H 41N9O7, 603.67. 
 
 
 
 
General procedure to conjugate RGD to platinum Complexes 
 
The carboxylic acid of trans-[PtCl2(4-picolinic acid)(isopropylamine)] and 
trans-[PtCl4(4-picolinic acid)(isopropylamine)] (0.01 mmol) was activated 
with 1.2 equiv. of EDC.HCl and N-hydroxysuccinimide (NHS) in dry 
CH2Cl2. After reacting at room temperature for 16 h under nitrogen, the 
solvent was evaporated and the yellow pail solid was washed with water 
to remove the urea by product. The solid was vacuum-dried. The 
activated ester were dissolved in CH3CN and added dropwise to a DMF 
solution (500 µL) containing the cyclo-RGD (0.003 g, 0.005 mmol) and 10 
equiv. of NaHCO3. After stirring for ∼3 h, the solvent was evaporated and 
the yellow solid was washed with CH2Cl2, dried, dissolved in water and 
purified by analytical RP-HPLC. After purification, RP-HPLC analysis 
(method B) was used to assess the purity (> 95%) of the recovered RGD-
containing Pt complexes (see Figure S6). 
 
Cyclo-RGD conjugate-PtII 
 
RP-HPLC (220 nm, gradient C): tR =19.8 min. ESI–MS (-) (m/z): 1068.7 
[M+Cl]- and 1032,8 [M-H]-, calc. for C36H53Cl2N11O8Pt 1033.86. 
 
į(195Pt, 64.53 MHz, MeOD,Na2PtCl6): −2380 ppm. 
 
Yield: 10 % (487 µg, 0.0005 mmol; İPhe (257 nm) = 200 L mol-1 cm-1) 
 
Cyclo-RGD conjugate-PtIV 
 
RP-HPLC (220 nm, gradient C): 95% (tR = 25.0 min). ESI–MS (+) (m/z): 
1146.8 [M+ACN+H])+, calc. for C36H53Cl4N11O8Pt 1104.76. 
 
Yield: 6 % (336 µg, 0.0003 mmol; İPhe (257 nm) = 200 L mol-1 cm-1) 
 
Cell culture 
 
Human Umbilical Vein Endothelial Cells (HUVEC) were cultured in 
supplemented EGM medium (Lonza). Human ovarian epithelial cancer 
cell lines (A2780 and SKOV3) were maintained in RPMI 1640 Medium. 
Human breast carcinoma cells (MCF-7 and MDA MB 231) and human 
adenocarcinoma (A549) were grown in DMEM. RPMI and DMEM culture 
mediums were supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) and 1% penicillin/streptomycin antibiotic solution. All culture 
mediums and supplements, except when indicated, were from Gibco, 
Invitrogen, UK. Cells were cultured in a humidified atmosphere of 95% air 
and 5% CO2 at 37 °C (Heraeus, Germany). 
 
Cytotoxicity 
 
The potential as antitumoral agents was explored by the evaluation of 
their effects on cellular proliferation using the [1-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium] (MTT) assay. Cells were seeded in 96-well 
culture plates at a density of 1.5 x 104 to 2.5 x 104 cells/well (depending 
of the cell line) and left to adhere overnight at 37 C. Cells were then 
incubated with the Pt complexes at different concentrations (0-200 µM) 
during 72h at 37 C and 5 % CO2. All tested compounds were first 
solubilized in DMSO (20 mM stock solution) and then diluted in culture 
medium for the assay, with the percentage of solvent in the culture never 
exceeding 0.1 %. After incubation, the compounds were removed and 
cells washed with PBS (200µL). The cellular viability was assessed by 
incubating cells with MTT (200 µL of 0.5 mg/mL soluti on in Modified 
Eagle’s εedium without phenol red) during 3h at 37 C. The εTT solution 
was removed and the insoluble and blue formazan crystals formed were 
dissolved and homogenized with DMSO (200 µL/well). The absorbance 
 
 
 
of this colored (purple) solution was quantified by measuring the 
absorbance at 570 nm, using a plate spectrophotometer (Power Wave 
Xs; Bio-Tek). A blank solution was prepared with DMSO alone (200 
µL/well). Each test was performed with at least six replicates. These 
results were expressed as percentage of the surviving cells in relation 
with the control incubated without compound. The maximum 
concentration of DMSO used in compounds solutions (0.1 %) was not 
cytotoxic. IC50 values were determined using the Graph Pad Prism 
software and expressed in micromolar concentrations. 
 
ICP-MS 
 
To explore the uptake of selected complexes and their intracellular 
distribution, cells were exposed to each complex (50 µM) for 24 h at 37 
°C, and then washed with cold PBS, collected by scrapping and 
centrifuged to obtain a cellular pellet. For the blocking experiments, an 
excess of cRGD (1mM) was used. The Pt content in the cell pellet was 
measured, after digestion, by ICP-MS on a ICP-MS NexION 300xx 
Perkin-Elmer instrument, with 187Rhenium used as internal standard. 
Briefly, samples were digested with ultrapure HNO3 (65 %), H2O2 and 
HCl, then evaporated and ressuspended in ultrapure water to obtain a 
2.0% (v/v) nitric acid solution. The relative standard deviation of the 
measurements (different aliquots from the same mother solution) was 
between 0.5 and 2.1%. 
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